|Articles|March 25, 2010

Infectious Disease Screening Not Performed at Many Substance Abuse Treatment Facilities

Fewer than half of all substance abuse treatment facilities surveyed nationwide reported that they conduct on-site infectious disease screening, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA). 

Rates of HIV, tuberculosis, sexually transmitted diseases, hepatitis, and hepatitis C are high among drug users. Injection drug users, in particular, are at increased risk for contracting HIV, hepatitis B, and hepatitis C. These diseases, if not identified and treated, can pose a significant health threat to both the individual with the disease and to the community.

“Arranging for screenings for infectious diseases should be a routine part of substance abuse treatment services,” said SAMHSA administrator Pamela S. Hyde, JD. “People enter treatment for different needs and screening provides an opportunity to identify additional healthcare needs as part of the recovery process.”

This study was based on data from the 2007 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of all known facilities in the United States, both public and private, that provide substance abuse treatment.  The survey solicits information regarding the provision of on-site screening for the following infectious diseases: hepatitis B, hepatitis C, HIV, sexually transmitted diseases and tuberculosis.  Key findings include:

-- The facilities that were most likely to provide infectious disease screening were operated by the federal government, followed by a state government.

-- More than half of the approximately 1,100 opioid treatment programs provided on-site screening for hepatitis B (62.1 percent), hepatitis C (64.1 percent), HIV (69.8 percent), sexually transmitted diseases (67.8 percent), or tuberculosis (93.3 percent).

-- Facilities that provided hospital inpatient treatment were more likely than facilities providing outpatient or non-hospital residential treatment to offer screening for hepatitis B, hepatitis C, HIV, sexually transmitted diseases, or tuberculosis.

-- Where available, the most common types of on-site screening were for tuberculosis, (34.3 percent), and HIV (29.7 percent).

 

 

 


Related to this article

Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.